A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic …

N Deng, LK Goh, H Wang, K Das, J Tao, IB Tan… - Gut, 2012 - gut.bmj.com
Objective Gastric cancer is a major gastrointestinal malignancy for which targeted therapies
are emerging as treatment options. This study sought to identify the most prevalent …

[HTML][HTML] Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

R Dienstmann, J Rodon, A Prat, J Perez-Garcia… - Annals of oncology, 2014 - Elsevier
The fibroblast growth factor receptor (FGFR) cascade plays crucial roles in tumor cell
proliferation, angiogenesis, migration and survival. Accumulating evidence suggests that in …

Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

J Tabernero, R Bahleda, R Dienstmann… - Journal of clinical …, 2015 - ascopubs.org
Purpose JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor
(FGFR) tyrosine kinase inhibitor. This first-in-human study evaluates the safety …

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives

MV Dieci, M Arnedos, F Andre, JC Soria - Cancer discovery, 2013 - AACR
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway
plays a fundamental role in many physiologic processes, including embryogenesis, adult …

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

AN Brooks, E Kilgour, PD Smith - Clinical cancer research, 2012 - AACR
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays
an important role in normal organ, vascular, and skeletal development. Deregulation of …

Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities

P Perez-Moreno, E Brambilla, R Thomas, JC Soria - Clinical cancer research, 2012 - AACR
Lung cancer is the leading cause of cancer-related deaths worldwide. Next to
adenocarcinoma, squamous cell carcinoma (SCC) of the lung is the most frequent histologic …

Discovery of pemigatinib: a potent and selective fibroblast growth factor receptor (FGFR) inhibitor

L Wu, C Zhang, C He, D Qian, L Lu, Y Sun… - Journal of Medicinal …, 2021 - ACS Publications
Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types.
Selective inhibition of FGFR has emerged as a promising approach for cancer treatment …

Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer

MT Herrera-Abreu, A Pearson, J Campbell… - Cancer discovery, 2013 - AACR
Activation of fibroblast growth factor receptors (FGFR) is a common oncogenic event. Little is
known about the determinants of sensitivity to FGFR inhibition and how these may vary …

Emerging therapeutic targets in metastatic progression: a focus on breast cancer

Z Li, Y Kang - Pharmacology & therapeutics, 2016 - Elsevier
Metastasis is the underlying cause of death for the majority of breast cancer patients.
Despite significant advances in recent years in basic research and clinical development …

FGFR as potential target in the treatment of squamous non small cell lung cancer

M Tiseo, F Gelsomino, R Alfieri, A Cavazzoni… - Cancer treatment …, 2015 - Elsevier
To date therapeutic options for squamous cell lung cancer patients remain scarce because
no druggable targets have been identified so far. Aberrant signaling by FGFs (fibroblast …